Avastin(bevacizumab)
Abevmy, Alymsys, Avastin, Avzivi, Aybintio, Mvasi, Onbevzi, Oyavas, Vegzelma, Zirabev (bevacizumab) is an antibody pharmaceutical. Bevacizumab was first approved as Lextemy on . It is used to treat colorectal neoplasms, fallopian tube neoplasms, glioblastoma, kidney neoplasms, and non-small-cell lung carcinoma amongst others in the USA. It has been approved in Europe to treat breast neoplasms, colorectal neoplasms, fallopian tube neoplasms, non-small-cell lung carcinoma, and ovarian neoplasms amongst others. The pharmaceutical is active against vascular endothelial growth factor A, long form. In addition, it is known to target Vascular permeability factor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Alymsys, Avastin, Jobevne, Mvasi, Vegzelma, Zirabev
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| alymsys | Biologic Licensing Application | 2022-04-27 |
| avastin | Biologic Licensing Application | 2025-01-06 |
| avzivi | Biologic Licensing Application | 2024-10-09 |
| jobevne | Biologic Licensing Application | 2025-04-01 |
| mvasi | Biologic Licensing Application | 2025-06-23 |
| vegzelma | Biologic Licensing Application | 2025-05-08 |
| zirabev | Biologic Licensing Application | 2025-01-22 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
bevacizumab, Avastin, Genentech, Inc. | |||
| 2027-05-29 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FG: Vegf/vegfr (vascular endothelial growth factor) inhibitors
— L01FG01: Bevacizumab
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01L: Ocular vascular disorder agents
— S01LA: Antineovascularisation agents
— S01LA08: Bevacizumab
Clinical
Clinical Trials
3583 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | 120 | 382 | 124 | 17 | 104 | 684 |
| Carcinoma | D002277 | — | C80.0 | 103 | 274 | 58 | 5 | 54 | 438 |
| Non-small-cell lung carcinoma | D002289 | — | — | 59 | 196 | 63 | 2 | 33 | 330 |
| Lung neoplasms | D008175 | — | C34.90 | 50 | 186 | 51 | 2 | 33 | 301 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 49 | 181 | 38 | 6 | 37 | 291 |
| Neoplasms | D009369 | — | C80 | 154 | 124 | 21 | 6 | 24 | 289 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 51 | 133 | 41 | 2 | 26 | 233 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 32 | 70 | 49 | 23 | 80 | 227 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 36 | 138 | 24 | 5 | 40 | 220 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 31 | 131 | 22 | 4 | 47 | 215 |
Show 54 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | — | 57 | 132 | 14 | — | 27 | 200 |
| Adenocarcinoma | D000230 | — | — | 35 | 85 | 28 | — | 8 | 138 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 26 | 64 | 9 | — | 11 | 95 |
| Glioma | D005910 | EFO_0000520 | — | 28 | 63 | 5 | — | 12 | 92 |
| Rectal neoplasms | D012004 | — | — | 19 | 63 | 8 | — | 8 | 90 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 29 | 41 | 3 | — | 2 | 61 |
| Uterine cervical neoplasms | D002583 | — | — | 17 | 37 | 13 | — | 5 | 61 |
| Gliosarcoma | D018316 | — | — | 10 | 35 | 1 | — | 1 | 42 |
| Squamous cell carcinoma | D002294 | — | — | 12 | 31 | 4 | — | 1 | 39 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 13 | 25 | 4 | — | — | 32 |
Show 134 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 8 | 24 | — | — | — | 28 |
| Healthy volunteers/patients | — | — | — | 23 | 2 | — | — | 1 | 26 |
| Cholangiocarcinoma | D018281 | — | C22.1 | 8 | 12 | — | — | — | 17 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 4 | — | — | 13 | 17 |
| Leukemia | D007938 | — | C95 | 7 | 11 | — | — | — | 16 |
| Central nervous system neoplasms | D016543 | — | — | 5 | 10 | — | — | 2 | 16 |
| Nervous system neoplasms | D009423 | — | — | 3 | 10 | — | — | 3 | 15 |
| Syndrome | D013577 | — | — | 8 | 9 | — | — | — | 14 |
| Oligodendroglioma | D009837 | EFO_0000631 | — | 6 | 12 | — | — | — | 14 |
| Multiple myeloma | D009101 | — | C90.0 | 3 | 9 | — | — | 1 | 12 |
Show 247 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Von hippel-lindau disease | D006623 | — | Q85.83 | 3 | — | — | — | 1 | 4 |
| Degenerative myopia | D047728 | — | H44.2 | 1 | — | — | — | 2 | 3 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 2 | — | — | — | — | 2 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 2 | — | — | — | — | 2 |
| Chondrosarcoma | D002813 | — | — | 2 | — | — | — | — | 2 |
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
| Hypoxia | D000860 | — | R09.02 | 1 | — | — | — | 1 | 2 |
| Hemangioma | D006391 | — | D18.0 | 2 | — | — | — | — | 2 |
| Pharyngeal neoplasms | D010610 | — | C14.0 | 2 | — | — | — | — | 2 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 2 | — | — | — | — | 2 |
Show 50 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 5 | 5 |
| Choroid diseases | D015862 | — | H31.9 | — | — | — | — | 3 | 3 |
| Intraocular pressure | D007429 | — | — | — | — | — | — | 2 | 2 |
| Vitrectomy | D014821 | — | — | — | — | — | — | 2 | 2 |
| Diabetes complications | D048909 | — | — | — | — | — | — | 2 | 2 |
| Sentinel lymph node biopsy | D021701 | — | — | — | — | — | — | 2 | 2 |
| Fluorescence | D005453 | — | — | — | — | — | — | 2 | 2 |
| Portal hypertension | D006975 | EFO_0000666 | K76.6 | — | — | — | — | 2 | 2 |
| Dry eye syndromes | D015352 | — | H04.12 | — | — | — | — | 2 | 2 |
| Wound infection | D014946 | — | — | — | — | — | — | 1 | 1 |
Show 58 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bevacizumab |
| INN | bevacizumab |
| Description | Bevacizumab, sold under the brand name Avastin, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. For age-related macular degeneration it is given by injection into the eye.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >7V5N:A,E|bevacizumab fab light chain
DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQP
EDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
>7V5N:B,F|bevacizumab fab heavy chain
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAY
LQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV
TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT |
Identifiers
| PDB | 6BFT, 7V5N |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201583 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00112 |
| UNII ID | 2S9ZZM9Q9V (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
VEGFA
VEGFA
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
NCBI Gene ID
—
Protein name
Vascular endothelial growth factor A
Protein synonyms
Vascular permeability factor
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 98,817 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
124,981 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use